Location · Dayton, OH
Clinical trials in Dayton, OH
43 recruiting studies have a site in Dayton, and 9 of them accept healthy volunteers.
43 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 3
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.
Pfizer
- Location
- Dayton, OH + 101 other US sites
- Eligibility basics
- Ages 1 mo–7 mo
- RecruitingHealthy volunteersPhase 3
A Study of COVID-19 Vaccine(s) in Children and Adults
BioNTech SE
- Location
- Dayton, OH + 13 other US sites
- Eligibility basics
- Ages 5+
- RecruitingHealthy volunteersPhase 3
Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents
Pfizer
- Location
- Dayton, OH + 49 other US sites
- Eligibility basics
- Ages 1–17
- RecruitingHealthy volunteersPhase 3
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age
GlaxoSmithKline
- Location
- Dayton, OH + 14 other US sites
- Eligibility basics
- Ages 1–6
- RecruitingHealthy volunteers
Aptis PRUJ Prosthesis for the Treatment of Patients With Proximal Radial Ulna Joint Disorders.
Aptis Medical
- Location
- Dayton, OH + 5 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingHealthy volunteersPhase 3
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
GlaxoSmithKline
- Location
- Dayton, OH + 46 other US sites
- Eligibility basics
- Ages 1–1
- RecruitingHealthy volunteersPhase 3
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
GlaxoSmithKline
- Location
- Dayton, OH + 12 other US sites
- Eligibility basics
- Ages 1–1
- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- Dayton, OH + 35 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
Palisade Bio
- Location
- Dayton, OH + 27 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 4
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
Takeda
- Location
- Dayton, OH + 77 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
Generate Biomedicines
- Location
- Dayton, OH + 21 other US sites
- Eligibility basics
- Ages 12–80
- RecruitingPhase 2/Phase 3
ACP-204 in Adults With Alzheimer's Disease Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Dayton, OH + 34 other US sites
- Eligibility basics
- Ages 55–95
- RecruitingPhase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Sanofi
- Location
- Dayton, OH + 72 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 3
Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)
Ambros Therapeutics, Inc.
- Location
- Dayton, OH + 29 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Dayton, OH + 57 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Location
- Dayton, OH + 51 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
AstraZeneca
- Location
- Dayton, OH + 70 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Hoffmann-La Roche
- Location
- Dayton, OH + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
AstraZeneca
- Location
- Dayton, OH + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Eli Lilly and Company
- Location
- Dayton, OH + 24 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated…
Eccogene
- Location
- Dayton, OH + 65 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
Eli Lilly and Company
- Location
- Dayton, OH + 36 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Eli Lilly and Company
- Location
- Dayton, OH + 10 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 2
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
Lighthouse Pharmaceuticals, Inc.
- Location
- Dayton, OH + 36 other US sites
- Eligibility basics
- Ages 55–80